- Home
- INCY vs AVY Comparison
INCY vs AVY Comparison
Compare INCY & AVY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INCY
- AVY
- Stock Information
- Founded
- INCY 1991
- AVY 1935
- Country
- INCY United States
- AVY United States
- Employees
- INCY N/A
- AVY N/A
- Industry
- INCY Biotechnology: Commercial Physical & Biological Resarch
- AVY Containers/Packaging
- Sector
- INCY Health Care
- AVY Consumer Discretionary
- Exchange
- INCY Nasdaq
- AVY Nasdaq
- Market Cap
- INCY 13.4B
- AVY 14.4B
- IPO Year
- INCY 1993
- AVY N/A
- Fundamental
- Price
- INCY $65.06
- AVY $177.69
- Analyst Decision
- INCY Hold
- AVY Buy
- Analyst Count
- INCY 19
- AVY 11
- Target Price
- INCY $72.67
- AVY $206.05
- AVG Volume (30 Days)
- INCY 1.8M
- AVY 640.4K
- Earning Date
- INCY 04-29-2025
- AVY 07-22-2025
- Dividend Yield
- INCY N/A
- AVY 2.12%
- EPS Growth
- INCY N/A
- AVY 27.06
- EPS
- INCY 0.10
- AVY 8.69
- Revenue
- INCY $4,413,226,000.00
- AVY $8,752,700,000.00
- Revenue This Year
- INCY $13.29
- AVY $2.08
- Revenue Next Year
- INCY $10.43
- AVY $3.97
- P/E Ratio
- INCY $592.09
- AVY $20.45
- Revenue Growth
- INCY 17.13
- AVY 3.58
- 52 Week Low
- INCY $53.56
- AVY $157.00
- 52 Week High
- INCY $83.95
- AVY $233.48
- Technical
- Relative Strength Index (RSI)
- INCY 60.01
- AVY 50.25
- Support Level
- INCY $63.51
- AVY $177.72
- Resistance Level
- INCY $66.26
- AVY $181.63
- Average True Range (ATR)
- INCY 1.60
- AVY 3.05
- MACD
- INCY 0.32
- AVY -0.32
- Stochastic Oscillator
- INCY 83.12
- AVY 21.95
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
About AVY Avery Dennison Corporation
Avery Dennison manufactures pressure-sensitive materials, merchandise tags, and labels. The company also runs a specialty converting business that produces radio-frequency identification, or RFID, inlays and labels. Avery Dennison draws a significant amount of revenue from outside the United States, with international operations accounting for the majority of total sales.